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Background: Neuroinflammation mediated by overactivated microglia plays a key role in many neurodegenerative
diseases, including Alzheimer’s disease (AD). In this study, we investigated for the first time the anti-neuroinflammatory
effects and possible mechanisms of SCM-198 (an alkaloid extracted from Herbaleonuri), which was previously found highly
cardioprotective, both in vitro and in vivo.
Methods: For in vitro experiments, lipopolysaccharide (LPS) or β-amyloid1-40 (Aβ1-40) was applied to induce microglial
overactivation. Proinflammatory mediators were measured and activations of NF-κB and mitogen-activated protein
kinases’ (MAPKs) pathways were investigated. Further protective effect of SCM-198 was evaluated in microglia-neuron
co-culture assay and Sprague-Dawley (SD) rats intrahippocampally-injected with Aβ1-40.
Results: SCM-198 reduced expressions of nitric oxide (NO), TNF-α, IL-1β and IL-6 possibly via, at least partially, inhibiting
c-Jun N-terminal kinase (JNK) and NF-κB signaling pathways in microglia. Co-culture assay showed that activated microglia
pretreated with SCM-198 led to less neuron loss and decreased phosphorylation of tau and extracellular signal-regulated
kinase (ERK) in neurons. Besides, SCM-198 also directly protected against Aβ1-40-induced neuronal death and lactate
dehydrogenase (LDH) release in primary cortical neurons. For in vivo studies, SCM-198 significantly enhanced cognitive
performances of rats 12 days after intrahippocampal injections of aged Aβ1-40 peptides in the Morris water maze
(MWM), accompanied by less hippocampal microglial activation, decreased synaptophysin loss and phosphorylation of
ERK and tau. Co-administration of donepezil and SCM-198 resulted in a slight cognitive improvement in SD rats 50 days
after intrahippocampal injections of aged Aβ1-40 peptides as compared to only donepezil or SCM-198 treated group.
Conclusions: Our findings are the first to report that SCM-198 has considerable anti-neuroinflammatory effects on
inhibiting microglial overactivation and might become a new potential drug candidate for AD therapy in the future.
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Alzheimer’s disease (AD), the most common form of de-
mentia among the elderly, is a chronic progressive disease
characterized by cerebral deposition of senile plaques com-
posed of amyloid-β (Aβ) peptides, intraneuronal neurofib-
rillary tangles originating from hyperphosphorylation of tau
protein, profound loss of neurons and neuroinflammation* Correspondence: yizhunzhu@gmail.com
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unless otherwise stated.[1-3]. Since the first patient with dementia described by
Alois Alzheimer in 1907, many therapeutic strategies for
AD have been proposed: acetylcholinesterase inhibi-
tors, N-methyl-D-aspartate receptor antagonists, anti-
amyloid therapies, drugs targeting tau protein and
mitochondrial dysfunction, and so on [4]. Previous
studies show that long-term use of NSAIDs lowers the
risk of developing AD, alleviates neuroinflammation, sup-
presses senile plaques and improves tau pathology and
cognition of different transgenic mice, but is accom-
panied by gastrointestinal, cardiovascular or nephro-
toxicity [5,6].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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crucial role in AD progression. Microglia, primary immune
cells of the brain, contribute largely to the neuroinflamma-
tory responses. Under normal conditions, microglia take
on a resting state with a ramified morphology and
execute their surveillance and protective functions by
extraction and retraction of their processes [7-9].
When the homeostasis of the central nervous system
(CNS) is perturbed, they become activated with an
amoeboid morphology accompanied by generations of
free radicals, cytokines, chemokines and acute-phase
proteins [10]. It is reported that Aβ aggregates and
relative products from dead cells could activate micro-
glia via Toll-like receptors (TLR) and receptors for ad-
vanced glycation end product-dependent pathways and
promote release of proinflammatory factors, such as
TNF-α, IL-1β and IL-6, which might in turn aggravate
the disease [11]. In postmortem brains from AD pa-
tients and animals, most reactive microglia are located
around dense-core Aβ plaques and elevated proinflam-
matory factors are also found in those brains which re-
veal the negative impact of neuroinflammation on AD
progression [8]. Therefore, therapeutic drugs based on
inhibiting microglial overactivation with less toxicity
seem to be promising.
SCM-198 (4-guanidino-n-butyl syringate, also named
Leonurine), a unique single compound existing only in
Herbaleonuri, has been previously found to improve anti-
oxidant capacity of myocardium [12], promote angiogenesis
in ischemic myocardium and ameliorate endothelial dys-
function caused by hyperlipidemia [13]. During 2010 to
2011, SCM-198 was surprisingly found to be effective in
stroke and Parkinson’s disease models via modulating
mitochondrial functions and the redox state of the brain,
respectively [14,15], which encouraged us to continuously
explore its possible therapeutic potential in AD models.
Aβ peptides induce neurotoxicity in multiple ways, in-
cluding oxidative stress, apoptosis or inflammation [16].
Meanwhile, SCM-198 has very good antioxidant, and
anti-apoptotic neuro-and cardioprotective effects both
in vitro and in vivo. Therefore, for investigating possible
anti-neuroinflammatory mechanisms of SCM-198 in
microglia, lipopolysaccharide (LPS), which is a very com-
mon agent for neuroinflammation studies, or aged Aβ1-40
peptides, was used to induce inflammatory responses
in vitro. LPS, a component of Gram-negative bacterial
cell wall, could activate TLR4 signalling, activate micro-
glia and promote production of proinflammatory cyto-
kines and related signaling pathways [17]. For in vivo
studies, Aβ1-40-injected Sprague-Dawley (SD) rats were
used to investigate the overall neuroprotective effect of
SCM-198 on cognitive impairments and microglial over-
activation. Our data indicated that SCM-198 could exert
neuroprotective and anti-inflammatory effects both inAβ1-40-injected rats and overactivated microglia, possibly
via inhibition of NF-κB activation and c-Jun N-terminal
kinase (JNK) pathways. This is also the first time that
great hope could be placed on this new compound for its





ide (MTT), BSA were purchased from Amresco (Solon,
OH, USA). Ibuprofen (IBU), poly-d-lysine, phosphatase
inhibitor cocktails, sulforhodamine B (SRB) and LPS were
purchased from Sigma-Aldrich (St Louis, MO, USA). In-
hibitors of mitogen-activated protein kinases (MAPKs)
were from Cayman (Ann Arbor, MI, USA). Plasmocin was
from Invivogen (San Diego, CA, USA). Primers were syn-
thesized by Sangon (Shanghai, China) and all reagents for
real-time reverse transcription-polymerase chain reaction
(RT-PCR) and cell culture were from Takara (Dalian,
China) and Gibco (Grand Island, NY, USA), respectively.
Donepezil (DON) hydrochloride (purity > 99%) was sup-
plied by Energy Chemical (Shanghai, China). SCM-198
(purity > 99%) was synthesized as previously described
[15]. For in vitro studies, IBU, DON and SCM-198 were
dissolved in dimethyl sulfoxide (DMSO) at concentrations
of 0.5 M, 2 × 10−2 M and 10−2 M, respectively, and were
diluted appropriately with cell culture medium (final
DMSO concentration ≤ 1‰). For in vivo studies, DON
and SCM-198 were dissolved in 0.9% sodium chloride so-
lution containing 1% (w/v) sodium carboxymethylcellulose
(CMC-Na). Lyophilized Aβ1-40 (ChinaPeptides, Shanghai,
China) was first dissolved in sterilized distilled water
followed by dilution with calcium-free PBS to a final
concentration of 1 mg/ml. This solution was aggre-
gated at 37°C for 7 days before its application in in vitro
experiment or in the surgery.
Cell culture
Cerebral cortex of newborn SD rats was separated and
cut into small pieces after removing meninges and blood
vessels to prepare mixed glial cells. Trypsinization (15 to
30 minutes, 37°C) with 0.125% trypsin was stopped with
DMEM/F12 medium containing 10% FBS, 100 units/ml
penicillin, 100 μg/ml streptomycin and 5 μg/ml plasmo-
cin. The tissue was gently pipetted to obtain a single-cell
suspension, which was then transferred to a new centri-
fuge tube after standing at room temperature (RT) for
one to two minutes. This procedure was repeated three
or four times. Then cells were centrifuged at 200 g for
5 minutes, resuspended in fresh DMEM/F12 medium
and plated according to different protocols. Twenty-one
days later, microglial cells were purified by mild trypsiniza-
tion method [18]. For primary astrocyte culture, cortical
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When cells became confluent, astrocytes were purified by
shaking at 350 rpm at 37°C for 12 hours. The purity (>95%)
of primary microglia and astrocytes were confirmed with a
mouse monoclonal CD11b antibody (1:200, Santa Cruz
Biotechnology, Santa Cruz, CA,, USA) and a mouse mono-
clonal glial fibrillary acidic protein (GFAP) antibody (1:300,
Cell Signaling, Danvers, MA,USA), respectively.
Cerebral cortex from fetuses of 17 to 18 days of gesta-
tion was used to prepare neurons, as described previ-
ously with minor modifications [19,20]. Preparation of
single cell-suspension of neurons was the same with that
of mixed glial cells. Cells were maintained in neurobasal
medium supplemented with 2% B27, 0.5 mM L-glutam-
ine, 100 units/ml penicillin and 100 μg/ml streptomycin.
Medium was changed 24 hours after plating and every
three days thereafter. Neurons cultured for 10 to 14 days
were used in the experiments. The purity of neurons
(>95%) was confirmed using a rabbit polyclonal MAP2
antibody (1:150, Cell Signaling, Danvers, MA, USA).
Immortalized murine BV-2 microglial cell line was
first generated by Blasiet al. and retains many morpho-
logical and functional properties of primary microglia
[21]. Cells were maintained in DMEM supplemented
with 10% FBS, 100 units/ml penicillin and 100 μg/ml
streptomycin, and were passed twice a week.
Microglia/neuron co-culture
Microglia/neuron co-culture assay was performed as ac-
cording to Yuekui Li et al. [22] with minor modifica-
tions. Neurons and BV-2 cells were separately seeded
into 24-well (2 × 105 neurons/well and 1 × 105 BV-2
cells/insert) or 6-well (6 × 105 neurons/well and 5 × 105
BV-2 cells/insert) format transwell plates (0.4-μm pore-
size, Corning Costar, St Louis, MO, USA). BV-2 cells
were pretreated with or without 0.1 to 10 μM SCM-198
or 100 μM IBU for 2 hours and were stimulated with
1 μg/ml LPS for another 2 hours. Inserts containing BV-
2 cells were then washed with fresh serum-free DMEM
medium before placement into wells containing neurons
to exclude the possible influence of residual LPS, SCM-198
or IBU. Twenty-four hours after co-culture, neuronal pro-
teins were collected for Western blot analysis and neuronal
viability was measured by MTTassay.
Real-time RT-PCR analysis
Total RNA was extracted from BV-2 cells using TRIzol
reagent (Takara, Dalian, China) according to the manu-
facturer’s instructions. One microgram of total RNA of
each sample was reverse transcribed into cDNAs using
the PrimeScript® RT Master Mix Perfect Real Time kit
(Takara, Dalian, China). The resulting cDNAs were amp-
lified by using a SYBR® Premix Ex TaqTM kit in iQ™5
real-time PCR detection system (Bio-Rad, Hercules, CA,USA) at 95°C for 30 seconds, 40 cycles at 94°C for
10 seconds and 60°C for 30 seconds, followed by 1 mi-
nute at 95°C, 1 minute at 60°C and finally 71 cycles at
60°C. Gene expressions of TNF-α, IL-1β, IL-6 and indu-
cible nitric oxide synthase (iNOS) were analyzed with β-
actin as an internal control. The primer sequences are
listed below:
(1) IL-6 [GenBank;NM_031168]: 5′-TTCCA
TCCAGTTGCCTTCTTG-3′ and 5′-TA
TCCTCTGTGAAGTCTCCTCTC-3′
(2) IL-1β [GenBank:NM_008361]: 5′-ATCT
CGCAGCAGCACATCAAC-3′ and 5′-TG
TTCATCTCGGAGCCTGTAGT-3′
(3) TNF-α [GenBank:NM_013693]: 5′-CGTG
GAACTGGCAGAAGAGG-3′ and 5′-TCA
GTAGACAGAAGAGCGTGGT-3′
(4) iNOS [GenBank:NM_010927]: 5′-GGACGAG
ACGGATAGGCAGAGATT-3′ and 5′-AAG
CCACTGACACTTCGCACAA-3′




Cells or rat hippocampus were lysed for 30 minutes on
ice in radioimmunoprecipitation assay (RIPA)lysis buffer
(Beyotime, Shanghai, China) supplemented with 1 mM
phenyl methanesulfonyl fluoride, 1% phosphatase inhibi-
tor cocktail 2 and 3. Supernatants were collected after
centrifugation at 16,200 g for 20 minutes at 4°C and
protein concentrations were measured using a BCA-100
Protein Quantitative Analysis kit (Shenergy Biocolor,
Shanghai, China). For the analysis of NF-κB p65 trans-
location, nuclear proteins of BV-2 cells were extracted
using NE-PER Nuclear and Cytoplasmic Extraction Re-
agents (Pierce, Rockford, IL, USA) according to the
manufacturer’s instructions. Equal amounts of proteins
were separated by 10 to 12% SDS-polyacrylamide gels
and transferred onto polyvinylidene fluoride membranes
(Millipore, Temecula, CA, USA). After blocking with 5%
skim milk at RT for 1 hour, membranes were incubated
with: polyclonal rabbit anti-NF-кB p65, monoclonal
rabbit anti-histone H3 (D1H2), monoclonal mouse anti-
IкBα (L35A5), monoclonal rabbit anti-phospho-p44/42
MAPK (ERK1/2) (Thr202/Tyr204), monoclonal rabbit
anti-p44/42 MAPK (Erk1/2) (137 F5), monoclonal rabbit
anti-phospho-p38 MAPK (Thr180/Tyr182) (D3F9), poly-
clonal rabbit anti-p38 MAPK, monoclonal rabbit anti-
phospho-SAPK/JNK (Thr183/Tyr185) (81E11), monoclonal
rabbit anti-SAPK/JNK (56G8), monoclonal mouse anti-
phospho-Tau (Ser396) (PHF13), monoclonal mouse
anti-Tau (Tau46), monoclonal rabbit anti-synaptophysin
(D35E4), monoclonal rabbit anti-β-tubulin (1:1,000, Cell
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phospho-Tau (Thr205), polyclonal rabbit anti-phospho-
Tau (Ser404) (1:1,000, Bioworld Technology, St Louis Park,
MN, USA) primary antibodies overnight at 4°C, followed
by incubation with appropriate horseradish peroxidase-
conjugated secondary antibodies for 1 hour at RT. Blots
were visualized using SuperSignal West Dura chemilu-
minescent substrate (Pierce, Rockford, IL, USA) in
Alpha Imager Detection System (Alpha Innotech, San
Leandro, CA, USA) and images were analyzed by ImageJ
software (NIH, USA).
Measurements of cell viability, cytokines, nitrite and
LDH leakage
Microglial cells were preincubated with or without 0.1
to 10 μM SCM-198, IBU or MAPK inhibitors for 2 hours
and stimulated with 1 μg/ml LPS for 24 hours or with
3 μM Aβ1–40 for 24 hours. Cell viability was measured
by MTT assay according to an earlier protocol [15].
TNF-α and IL-1β levels in supernatant were measured
using sandwich ELISA kits (Boatman Biotech, Shanghai,
China) according to the manufacturer’s instructions.
Nitrite was measured by Griess reaction: 100 μl of super-
natants were mixed with 100 μl of Griess reagent (2%
sulfanilamide, 5% H3P04 and 0.2% N-(1-naphthyl) ethyle-
nediaminedihydrochloride) and incubated for 15 minutes
at RT. The absorbance was measured at 546 nm and
NaNO2 (0 to 100 μM) was used as the standard.
Morphological changes of primary microglia were
observed using phase-contrast microscope (Carl Zeiss
Inc., Thornwood, NY, USA) and quantified by radius
ratio (radius ratio = maximum radius of cell/minimum
radius of cell) using Image-Pro Plus 6.0 Analysis Sys-
tem (Media Cybernetics, Rockville, MD, USA). Primary
cortical neurons were preincubated with or without 0.1
to 10 μM SCM-198 or DON for 2 hours and stimulated
with 20 μM aged Aβ1-40 for 12 hours. Neuron viability
was detected by SRB assay according to descriptions by
Wai H Yu et al. [23] and lactate dehydrogenase (LDH)
levels in the cell supernatants were determined using a
commercial kit (Jiancheng Bioengineering, Nanjing, China).
NF-кB nuclear translocation assay
BV-2 cells and primary microglia were pretreated with
or without 1 μM SCM-198, 100 μM IBU or 20 μM DON
and stimulated with 1 μg/ml LPS or 3 μM Aβ1-40 for
30 minutes. Cells were fixed with 4% paraformaldehyde
and blocked with 10% BSA for 1 hour at RT, then incu-
bated with monoclonal rabbit NF-κB p65 (D14E12)
antibody (1:50, Cell Signaling, Danvers, MA, USA) over-
night at 4°C, followed by stained with Alexa Fluor
488-conjugated goat anti-rabbit IgG (1:200, Molecular
Probes, Eugene, OR, USA) for 2 hours in dark at RT.
The nuclear translocation of NF-кB p65 was capturedusing fluorescence or confocal microscope (Carl Zeiss
Inc., Thornwood, NY, USA).
Surgery and drug administration
Sixty male SD rats (8 to 10 weeks old, 200 to 250 g)
(BiKai, Shanghai, China) were randomly divided into 6
groups: sham group, Aβ1-40 group (both treated with
0.9% saline containing 1% CMC-Na), Aβ1-40 + SCM-198
15, 30, 60 mg/kg groups, DON group (1.0 mg/kg, as
positive control). Drugs were given by gavage seven days
before surgery, followed by daily administration until the
end of the behavioral tests. Animals were provided with
ad libitum food and water, and housed 5 per cage in a
specific pathogen-free environment with 12-hour light/
dark cycle and constant temperature (22°C ± 1°C). Seven
days after drug pretreatment, rats were anesthetized with
7% chloral hydrate and positioned in a stereotaxic frame
(Stoelting Co., Wood Dale, IL, USA). Two micrograms
per liter of aggregated Aβ1-40 (5 μl/side, for Aβ1-40,
Aβ1-40 + SCM198 15, 30, 60 mg/kg and DON groups) or
vehicle (5 μl/side, for sham group) was bilaterally injected
into the hippocampus at a rate of 0.5 μl/minute (coordi-
nates: AP = −3.0 mm; ML= ± 2.2 mm; DA= −2.8 mm).
Twelve days after surgery, Morris water maze (MWM) was
applied to evaluate the spatial memory of the animals.
For investigating whether SCM-198 could improve the
effect of DON, which is at the moment a palliative drug
used in clinical management of AD, 45 male SD rats (8
to 10 weeks old, 200 to 250 g) (BiKai, Shanghai, China)
were randomly divided into 5 groups: sham group,
Aβ1-40 group (both treated with 0.9% saline containing
1% CMC-Na), Aβ1-40 + SCM-198 60 mg/kg groups,
Aβ1-40 + DON 1 mg/kg group and Aβ1-40 + SCM-198
60 mg/kg + 1 mg/kg group DON group. Fifty days after
surgery, MWM was applied to evaluate the possible long-
lasting effect of SCM-198 and co-administration of SCM-
198 and DON. All animal experiments conformed to
guidelines of Regulations of Experimental Animal Adminis-
tration of PR China (14 November 1988) and were approved
by the Animal Ethics Committee of Fudan University.
Morris water maze (MWM)
Animals were tested in the MWM for assessment of spatial
reference memory in a room with constant temperature
(23 ± 1°C) and humidity (around 50%). The apparatus con-
sists of a transparent platform (9 cm in diameter) and a
black Plexiglas circular pool (160 cm in diameter) which is
equally divided into 4 quadrants. Spatial cues of different
geometric shapes and colors were fixed on the upper wall
of the pool and water temperature was kept at 21 ± 1°C. A
four-day protocol was conducted: during the acquisition
phase (from the first day to the third day), the platform was
fixed in the middle of one quadrant (target quadrant) and
submerged 1 to 2 cm below the water surface. Each rat was
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one or two minutes randomly from two different starting
points equidistant from the platform. The time for finding
the platform was defined as escape latency. If animals failed
to locate the hidden platform within two minutes, they
were gently guided onto the platform and left there for ten
seconds. On the fourth day, the platform was removed and
each rat was given one minute to swim in the pool. Time
spent in the target quadrant, swimming speed and paths
was recorded and analyzed by the Doctor Mice software
(Mobile Datum, Shanghai, China) [24].
Histology
Rats were transcardially perfused with 0.9% saline followed
by ice-cold 4% paraformaldehyde. The brains were fixed in
the same fixative for 3 days and then in 30% sucrose for
4 days at 4°C. Thirty-micron coronal sections were made
using a cryostat microtome (Thermo Fisher Scientific, Wal-
tham, MA, USA). Sections were incubated in 0.3% Triton
X-100 for 30 minutes, followed by 17 minutes in methanol/
3% H2O2 (v/v, 1:1) solution. After blocked with a solution
containing 5% BSA, 5% goat serum and 0.1% NaN3,
sections were incubated with goat polyclonal anti-iba-1
antibody (1:500, Abcam, Cambridge, MA, USA) overnight
at 4°C, then stained with MaxVision™ HRP-Polymer anti-
Goat IHC Kit (Maixin-Bio, Fuzhou, China) for 15 minutes
at RT. Microglia were visualized using a diaminobenzidine
kit (Boster, Wuhan, China), and photographed by a phase-
contrast microscope (Carl Zeiss Inc., Thornwood, NY,
USA). Integrated optical density (IOD) of iba-1 expression
was calculated using Image-Pro Plus 6.0 Analysis System
(Media Cybernetics, Rockville, MD, USA).
Statistical analysis
Data were expressed as mean ± SEM and analyzed either
by one-way analysis of variance (ANOVA) or two-way
repeated-measures ANOVA followed by Tukey’s post-hoc
analysis using GraphPad Prism (La Jolla, CA, USA). Values
of P < 0.05 were considered statistically significant.
Results
SCM-198 inhibited LPS- or Aβ1-40-induced proinflammatory
mediator release in microglia and astrocytes and prevented
morphological alterations in microglia
No obvious cytotoxicity was observed for 0.001 to
100 μM SCM-198 (data not shown). Possible anti-
neuroinflammatory mechanisms of SCM-198 were
studied mainly using BV-2 cells in vitro. As nitric oxide
(NO) and cytokines, such as TNF-α, IL-1β and IL-6,
are indicators of inflammatory process, we first investi-
gated the inhibitory effects of SCM-198 on NO and
proinflammatory cytokine release induced by LPS or
Aβ1-40 in microglia. Two-hour pretreatment of BV-2
cells with 1 to 10 μM SCM-198 or 100 μM IBU couldsignificantly suppress upregulation of iNOS, TNF-α,
IL-1β and IL-6 mRNA expressions (F (5, 26) = 17.42, P <
0.0001, Figure 1a; F (5, 45) = 6.42, P = 0.0001, Figure 1b;
F (5, 24) = 6.56, P = 0.0006, Figure 1c; F (5, 16) = 10.27, P =
0.0002, Figure 1d, respectively) induced by 2-hour exposure
to 1 μg/ml LPS. Two-hour pretreatment of BV-2 cells with
1 to 10 μM SCM-198 or 100 μM IBU also inhibited NO,
IL-1β and TNF-α productions after 24-hour incubation
with 1 μg/ml LPS (F (5, 54) = 4.08, P = 0.0033, Figure 1e; F
(5, 12) = 9.50, P = 0.0007, Figure 1f; F(5, 17) = 10.23, P =
0.0001, Figure 1g, respectively). TNF-α production induced
by 24-hour exposure with 1 μg/ml LPS also decreased
under pretreatment of 1 to 10 μM SCM-198 or IBU in pri-
mary microglia (F (5, 12) = 15.59, P < 0.0001, Figure 1h).
Twenty-four-hour incubation with 3 μM Aβ1-40 doubled
the production of TNF-α in BV-2 cells, which was effect-
ively inhibited by 2-hour pretreatment of 1 to 10 μM SCM-
198 or 20 μM DON (F(5, 18) = 14.74, P < 0.0001, Figure 1i).
Forty-eight-hour stimulation of astrocytes with 10 μM
Aβ1-40 also increased NO and TNF-α productions, which
could also be significantly inhibited by 0.1 to 10 μM SCM-
198 or 20 μM DON (F(5, 84) = 7.022, P < 0.0001, Figure 1j;
F (5, 48) = 6.177, P = 0.0002, Figure 1k, respectively).
Morphological studies (Figure 2) showed that primary
microglia became activated and took on an amoeboid
shape (radius ratio decreased by nearly 75% and 67%,
respectively) after 24-hour LPS or Aβ1-40 stimulation,
while pretreatment of 1 μM SCM-198 or IBU or DON in
some extent helped to prevent this cellular transformation
(F (3, 12) = 48.66, P < 0.0001, Figure 2c; F (3, 336) = 9.794,
P < 0.0001, Figure 2d).
SCM-198 inhibited activation of JNK and NF-кB pathways
induced by LPS in BV-2 cells
One microgram per milliliter LPS induced inhibitor of NF-
κB (IкB-α) degradation and phosphorylation of MAPKs
(Figure 3a), including extracellular signal-regulated kinase
(ERK), JNK and p38, in a time-dependent manner in BV-2
cells (F (7, 24) = 5.36, P = 0.0009, Figure 3b; F (7, 40) = 2.52,
P = 0.0305, Figure 3c; F (7, 16) = 36.58, P < 0.0001, Figure 3d;
F (7, 16) = 26.17, P < 0.0001, Figure 3e, respectively), while
3 μM Aβ1-40 could also mildly induce similar IкB-α degrad-
ation andMAPKs phosphorylation in BV-2 cells, and 30 mi-
nutes was chosen as the optimal time for LPS or Aβ1-40
stimulation. Two-hour pretreatment with SCM-198 could
significantly inhibit JNK phosphorylation and IкB-α degrad-
ation, but not ERK and p38 (Figure 3f; F (5, 23) = 5.47, P =
0.0018, Figure 3g; F (5, 44) = 6.27, P = 0.0002, Figure 3h; F
(5, 24) = 7.63, P = 0.0002, Figure 3i; F (5, 27) = 74.44, P <
0.0001, Figure 3j, respectively; Figure 4a; F (5, 30) = 6.585,
P = 0.0003, Figure 4b; F (5, 24) = 4.772, P = 0.0036, Figure 4c;
F (5, 18) = 7.959, P = 0.0004, Figure 4d; F (5, 18) = 16.00,
P < 0.0001, Figure 4e, respectively). Inhibitory effects of
SCM-198 on NO and TNF-α production could be
Figure 1 SCM-198 inhibited lipopolysaccharide (LPS)- or Aβ1-40-induced proinflammatory mediator release in microglia and astrocytes.
BV-2 cells were pretreated with indicated concentrations of SCM-198(SCM) or ibuprofen (IBU) for 2 hours, then stimulated with 1 μg/ml LPS for
another 2 hours. mRNA expressions of iNOS (a), TNF-α (b), IL-1β (c) and IL-6 (d) were analyzed by real-time RT-PCR. BV-2 cells were pretreated
with indicated concentrations of SCM or IBU for 2 hours, followed by 24-hour incubation with 1 μg/ml LPS, nitric oxide (NO) (e), IL-1β (f), TNF-α
(g) levels in the cell culture medium were detected by Griess reaction and ELISA assay, respectively. Primary microglia were pretreated the same
way as described above, followed by 24-hour incubation with 1 μg/ml LPS. TNF-α (h) level in the cell culture medium was measured by ELISA
assay. BV-2 cells were pretreated with the indicated concentrations of SCM or 20 μM donepezil (DON) for 2 hours, followed by 24-hour stimulation with
3 μM Aβ1-40. TNF-α (i) in the cell culture medium was measured by ELISA assay. Primary astrocytes were pretreated with indicated concentrations of SCM
or 20 μM donepezil (DON) for 2 hours, followed by 48-hour stimulation with 10 μM Aβ1-40. NO (j) and TNF-α (k) levels in the cell culture
medium was measured by Griess reaction and ELISA assay, respectively. *P < 0.05, **P < 0.01, ***P < 0.001, Tukey’s test versus only LPS- or
only Aβ1-40-treated group; #P < 0.05, ##P < 0.01, ###P < 0.001, Tukey’s test versus control group.
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of JNK, in BV-2 cells (F (4, 24) = 10.42, P < 0.0001,
Figure 5a; F (4, 53) = 16.55, P < 0.0001, Figure 5b, re-
spectively). NF-кB, ubiquitously expressed in almostevery organ, plays crucial roles in inflammation and
was found to be activated around senile plaques in AD
patients’ brains [25]. In our study, a 30-minute stimu-
lation of 1 μg/ml LPS or 3 μM Aβ1-40 activated the NF-
Figure 2 SCM-198 prevented lipopolysaccharide (LPS)- or Aβ1-40-induced morphological alterations in microglia. BV-2 cells or primary
microglia were pretreated with indicated concentrations of 1 μM SCM-198(SCM), 100 μM ibuprofen (IBU) or 20 μM donepezil (DON) for 2 hours,
then stimulated with 1 μg/ml LPS (a) or 3 μM Aβ1-40 (b) for 24 hours. Morphological changes were quantified by measuring radius ratio (radius
ratio = maximum radius/minimum radius) (c-d) (scale bar, 100 μm). Data represent mean ± SEM of more than three independent experiments.
*P < 0.05, **P < 0.01, ***P < 0.001, Tukey’s test versus only LPS- or only Aβ1-40-treated group; #P < 0.05, ##P < 0.01, ###P < 0.001, Tukey’s test versus
control group.
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the nucleus in both BV-2 cells (Figure 5c, left panel of each
group) and primary microglia (Figure 5c, right panel of
each group, Figure 5d). Two-hour pretreatment with 1 μM
SCM-198 or 100 μM IBU or 20 μM DON could signifi-
cantly diminish this effect (Figure 5c-5d).
SCM-198 directly protected neurons or indirectly
protected neurons via modulating microglia in microglia/
neuron co-culture system
As SCM-198 could effectively inhibit microglial over-
activation, we then ventured into how these ‘SCM-198- or
IBU-pretreated’ microglia would interact with neurons. A
co-culture system was applied to investigate whether
SCM-198 could protect neurons indirectly via directly
suppressing overactivated microglia. LPS-preactivated
or ‘SCM-198- or IBU-pretreated’ BV-2 cells in inserts
were washed twice with fresh DMEM medium to re-
move residual LPS, SCM-198 or IBU. These washed
cells in inserts were then placed into wells containingprimary neurons and were co-cultured for 24 hours.
Between inserts and wells, there is a semi-permeable
membrane (0.4-μm pore-size) which blocks the direct
contact between neurons and microglia, but allows
exchange of molecules. LPS-preactivated BV-2 cells
caused a decrease in neuronal viability which was re-
versed by ‘SCM-198- or IBU-pretreated’ microglia and
1 μM SCM-198 turned out to be the optimal dose (F (5,
12) = 9.984, P = 0.0006, Figure 6a). Accordingly, West-
ern blot showed that phosphorylation of ERK and tau
in neurons were repressed by SCM-198 (Figure 6b, F
(5, 50) = 4.27, P = 0.0026, Figure 6c; F (5, 30) = 3.40,
P = 0.0150, Figure 6d, F (5, 12) = 5.599, P = 0.0069,
Figure 6e; F (5, 24) = 8.544, P < 0.0001, Figure 6f,
respectively), indicating that SCM-198 could indirectly
protect primary neurons through suppressing micro-
glial overactivation. Meanwhile, SCM-198 could also
directly protect neurons from 20 μM Aβ1-40-induced
neuronal death (F (5, 18) = 7.07, P = 0.0008, Figure 6g)
and LDH leakage (F (5, 30) = 23.41, P < 0.0001, Figure 6h).
Figure 3 SCM-198 inhibited lipopolysaccharide(LPS)-induced c-Jun N-terminal kinase (JNK) phosphorylation and IкB-α degradation in
BV-2 cells. Exposure of BV-2 cells to 1 μg/ml LPS led to a time-dependent IкB-α degradation (a, b) and phosphorylation of ERK (p-ERK) (a, c),
JNK (p-JNK) (a, d) and p38 (p-p38) (a, e). BV-2 cells were pretreated with 0.1 to 10 μM SCM, 100 μM ibuprofen (IBU), 10 μM SP600125 (SP), 10 μM
PD98059 (PD), or 20 μM SB203580 (SB) for 2 hours, followed by 30-minute LPS stimulation. SCM could inhibit JNK activation (f, g) and IкB-α
degradation (f, j), but not ERK (f, h) and p38 activation (f, i). Data represent mean ± SEM of more than three independent experiments. *P < 0.05,
**P < 0.01, ***P < 0.001, Tukey’s test versus only LPS-treated group; #P < 0.05, ##P < 0.01, ###P < 0.001, Tukey’s test versus control group.
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SD rats in MWM test
To further explore neuroprotective effects of SCM-198
in vivo, SD rats with bilateral intrahippocampal injections
of aggregated Aβ1-40 were applied. As the experimentprogressed, average escape latencies of all groups gradually
decreased, with no significant differences observed from
trial 1 to trail 3 (F (5, 53) = 2.06, P = 0.085; F (5, 53) = 0.98,
P = 0.440; F (5, 53) = 1.11, P = 0.3668, respectively,
Figure 7a). Up to trial 4, a dramatically significant
Figure 4 SCM-198 also inhibited Aβ1-40-induced c-Jun N-terminal kinase (JNK) phosphorylation and IкB-α degradation in BV-2 cells.
BV-2 cells were pretreated with 0.1 to 10 μM SCM, 20 μM donepezil (DON), 10 μM SP600125 (SP), 10 μM PD98059 (PD), or 20 μM SB203580 (SB)
for 2 hours, followed by 30-minute Aβ1-40 stimulation. SCM could inhibit JNK activation (a, b) and IкB-α degradation (a, e), but not ERK (a, c)
and p38 activation (a, d). Data represent mean ± SEM of more than three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, Tukey’s test
versus only Aβ1-40-treated group; #P < 0.05, ##P < 0.01, ###P < 0.001, Tukey’s test versus control group.
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SCM-198-treated group as compared with that of only
Aβ1-40-treated group (F (5, 53) = 4.70, P = 0.0013, Figure 7a).
In trial 5 and trial 6, rats administered with 30 mg/kg
SCM-198 also showed considerable cognitive improve-
ments (F (5, 53) = 4.10, P = 0.0032; F (5, 53) = 4.00,
P = 0.0037, respectively, Figure 7a). Time spent in the
target quadrant was assessed during probe trial (Day
4). Figure 7b showed that SCM-198 enhanced spatial
memory of rats in a dose-dependent manner (F (5, 53) =
5.44, P = 0.0004, Figure 7b). Two-way repeated-measures
ANOVA analysis showed a significant effect of drug treat-
ment (F (5, 265) = 8.667, P < 0.0001) and trial effect (F (5,
265) = 84.80, P < 0.0001). Body weight remains normal and
no statistical differences were found in swimming speed of
rats between groups throughout the experiment (data not
shown). DON (1 mg/kg), a first-line inhibitor of acetyl-
cholinesterase and now clinically used for AD treatment,
was used as the positive control [26]. Taken together, be-
havioral data indicated that SCM-198 could amelioratecognitive impairments in a time- and dose-dependent man-
ner with 60 mg/kg as the optimal dose.SCM-198 alleviated microglial activation, decreased
phosphorylation of ERK and tau, inhibited synaptophysin
loss and NF-кB p65 activation in vivo
Intrahippocampal injections of Aβ1-40 led to elevated
ERK phosphorylation, NF-кB p65 activation, increased
tau phosphorylation, and synaptophysin loss, which were
significantly reversed by SCM-198 treatment in a dose-
dependent manner, with 60 mg/kg as the optimal dose
(Figure 7c, F (5,27) = 4.44, P = 0.0045, Figure 7d; F (5,18) =
13.23, P < 0.0001, Figure 7e; F (5,36) = 6.93, P = 0.0001,
Figure 7f; F (5,31) = 6.13, P = 0.0005, Figure 7g, respect-
ively). Immunostains of brain slices against iba-1 (Figure 7i)
showed that Aβ1-40 injections induced excessive microglial
activation at and around the injection site and SCM-198 at
60 mg/kg and DON could attenuate this activation (F (3,
20) = 22.04, P < 0.0001, Figure 7h).
Figure 5 SCM-198 inhibited microglia via c-Jun N-terminal kinase (JNK) and NF-кB pathways. BV-2 cells were pretreated with 1 μM SCM
or 10 μM SP (a specific inhibitor of JNK) for 2 hours, followed by 24-hour incubation with 1 μg/ml LPS. Nitric oxide (NO) (a) and TNF-α (b) in the
cell culture medium were measured by Griess reaction and ELISA assay, respectively. The inhibitory effect of SCM on NO and TNF-α production
could be mimicked by SP. BV-2 cells and primary microglia were both pretreated with 1 μM SCM, 100 μM ibuprofen (IBU) or 20 μM donepezil
(DON) for 2 hours, and stimulated with 1 μg/ml lipopolysaccharide (LPS) (c) or Aβ1-40 (d) for 30 minutes; NF-кB p65 translocation was observed
using fluorescence microscope (c, left panel of each group, BV-2 cells, scale bar, 100 μm) or confocal microscope (c-d, right panel of each group,
primary microglia, scale bar, 10 μm). Primary microglia were stained using CD11b antibody (d, microglial marker, red) and 4',6-diamidino-2-
phenylindole (DAPI) (nuclear staining, blue), purity of primary microglia is more than 95%. Data represent mean ± SEM of more than three
independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, Tukey’s test versus only LPS-treated group; #P < 0.05, ##P < 0.01, ###P < 0.001,
Tukey’s test versus control group.
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impairments in a chronic rat AD model induced by Aβ1-40
As described in the Material and Methods section, 45
male rats were pretreated with vehicle, 60 mg/kg SCM-
198, 1 mg/kg DON or co-administrated with SCM-198
and DON for 7 days. Fifty days after surgery, rats of only
the Aβ1-40-injected group showed more severe cognitive
impairments in spatial reference memory as compared
with that of rats of 12-day recovery from surgery. Even
up to trial 8, rats of only the Aβ1-40-injected group still
needed 37.3 seconds in average to find the invisible
platform. No significant differences were observed
from trial 1 to trail 4 (F (4, 40) = 1.292, P = 0.2895; F (4,
40) = 2.078, P = 0.1018; F (4, 40) = 2.40, P = 0.066; F (4,
40) = 2.603, P = 0.0502, respectively, Figure 8a). From
trial 5 to trial 8, therapeutic effects of SCM-198, DON
and co-administration of SCM and DON became sta-
tistically significant and animals of co-administrationgroup showed the best performances. (F (4, 40) = 4.517,
P = 0.0042; F (4, 40) = 6.299, P = 0.0005; F (4, 40) = 9.255,
P < 0.0001; F (4, 40) = 12.75, P < 0.0001, respectively,
Figure 8a). Two-way repeated-measures ANOVA ana-
lysis showed an extremely significant effect of drug
treatment (F (4, 280) = 21.41, P < 0.0001) and trial effect
(F (7, 280) = 35.76, P < 0.0001). Body weight remains
normal and no statistical differences were found in
swimming speed of rats between groups throughout the
experiment (data not shown). Time spent in the target
quadrant was also assessed during probe trial (Day 5).
Figure 8b showed that 60 mg/kg SCM-198, 1 mg/kg
DON and co-administration of SCM-198 and DON all
lengthened their stay in target quadrant with rats of
co-administration group spending the longest time
(F (5, 53) = 4.562, P = 0.004, Figure 8b), indicating that
SCM-198 could effectively improve the therapeutic ef-
fect of DON.
Figure 6 SCM-198 could directly protect neurons from Aβ1-40toxicity or indirectly protect neurons via modulating microglia in
microglia/neuron co-culture system. BV-2 cells were pretreated with 0.1 to 10 μM SCM or 100 μM ibuprofen (IBU), and stimulated with
1 μg/ml lipopolysaccharide (LPS) for 2 hours, washed with fresh DMEM medium and co-cultured with cortical neurons for 24 hours. Neuronal viability
was measured by 5-diphenyltetrazolium bromide (MTT) assay (a) and phosphorylation of ERK (p-ERK) and tau (p-tau) of neurons were detected by
Western blot (b-f). Primary cortical neurons were pretreated with indicated concentrations of SCM or 20 μM donepezil (DON) for 2 hours, followed by
12-hour stimulation of 20 μM Aβ1-40. Neuronal viability (g) and LDH leakage (h) were measure by sulforhodamine B (SRB) assay and the
lactate dehydrogenase (LDH) kit. Data represent mean ± SEM of more than three independent experiments. *P < 0.05, **P < 0.01, Tukey’s test
versus only LPS- or only Aβ1-40-treated group; #P < 0.05, ##P < 0.01, Tukey’s test versus control group.
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The role neuroinflammation plays in the pathological
development of AD still remains controversial today, as
inflammation itself is an innate defense against both en-
dogenous and exogenous insults under normal physio-
logical conditions. In neurodegenerative diseases like
AD, chronic long-lasting inflammation is considered, to
a great extent, as the driving force or even initiator of the
disease [3]. During this process, ramified resting microglia
undergo morphological changes including deramification,
process shortening and thickening and finally development
into its activated amoeboid form. Neurotoxic factors such
as proinflammatory cytokines and chemokines are subse-
quently released from activated microglia and lead to neur-
onal damage [27].
For the indispensable role of microglia in the brain,
therapeutic strategies of curbing microglial neurotoxicity
without affecting its viability would be feasible. Extensive
literatures have documented that IBU, one of the most
commonly used NSAIDs, could significantly inhibit acti-
vation of human primary microglia or THP-1 macro-
phages [28] and suppress brain inflammation [5,29-31].
Thus, IBU was chosen as the positive control for in vitro
study. Our data obtained from both primary microglia and
BV-2 cell line indicated considerable inhibitory effects of
SCM-198 on overactivated microglia via suppressing
proinflammatory cytokines and NO productions. Possible
underlying mechanisms were demonstrated to be, at leastpartially, through the inhibitions of NF-кB and JNK path-
ways. Microglial phenotype transition from amoeboid back
to ramified morphology was observed after SCM-198 treat-
ment (Figure 2), which was consistent with data from cyto-
kine and NO assays in microglia. Co-culture and in vivo
data provided further validations for the neuroprotective ef-
fects of SCM-198, which alleviated neuroinflammation via
modulating microglia and therefore improved overall cog-
nitive performances of rats. One thing of note is the opti-
mal dose of SCM-198 in in vitro experiments. In most
cases, SCM-198 at 1 μM exerted the best inhibitory effect
in microglia, while 10 μM sometimes became the optimal
dose. This could be possibly ascribed to different sensitiv-
ities between cell lineages (primary microglia versus BV-2
cells) (Figure 1g and 1h). Besides, 10 μM SCM-198 was
more effective than 1 μM SCM-198 in inhibiting NO pro-
duction (Figure 1a and 1e), while SCM-198 at 1 μM inhib-
ited transcriptions of proinflammatory cytokines more
effectively (Figure 1b-1d). We guessed that 10 μM SCM-
198 not only inhibited transcriptions of cytokines, but also
introduced some unknown mechanisms which unregulated
NO production to some extent. On the other hand, SCM-
198 at 1 and 10 μM could both inhibit proinflammatory
factors, which means a relatively broad therapeutic window
of this compound. Figure 1i showed that 3 μM Aβ1-40 also
upregulated TNF-α release after 24-hour incubation and
SCM-198 at 1 and 10 μM significantly inhibited this eleva-
tion. Meanwhile, in Figure 6g-6h, neurons died when
Figure 7 SCM-198 improved cognitive performances of Aβ1-40-injected Sprague-Dawley (SD) rats in the Morris water maze (MWM) test,
alleviated microglial activation, suppressed phosphorylation of extracellular signal-regulated kinase (ERK) and tau, inhibited NF-кB p65
translocation and synaptophysin loss in vivo. SD rats were subjected to bilateral microinjections of 2 μg/μl aggregated Aβ1-40 (5 μl/side) or
vehicle into hippocampus and MWM test was conducted 12 days after surgery. (a) Mean escape latency from Day 1 to Day 3; (b) time spent in
target quadrant. Data represent mean ± SEM of nine to ten rats per group. *P < 0.05, **P < 0.01, Tukey’s test versus only Aβ1-40-treated group;
#P< 0.05, ##P< 0.01, ###P< 0.001, Tukey’s test versus sham group. Phosphorylation of ERK (p-ERK) (c, d), nuclear p65 (NF-кB-p65) (c, e), phosphorylation
of tau (p-tau) (c, f) and synaptophysin loss (c, g) were analyzed by Western blot (n = 5 rats/group). (i) Examples of iba-1 staining for microglia (dark brown,
indicated by arrows) in hippocampus (scale bar, 100 μm; n = 3 rats/group). (h) Integrated optical density (IOD) for of iba-1 staining for microglia.
Data represent mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, Tukey’s test versus only Aβ1-40-treated group; #P < 0.05, ##P < 0.01, Tukey’s test
versus sham group.
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Figure 8 Synergistic effects of SCM-198 and donepezil on cognitive impairments in a chronic rat Alzheimer’s disease (AD) model
induced by Aβ1-40. SD rats were subjected to bilateral microinjections of 2 μg/μl aggregated Aβ1-40 (5 μl/side) or vehicle into hippocampus
and Morris water maze (MWM) test was conducted 50 days after surgery. (a) Mean escape latency from Day 1 to Day 4; (b) time spent in target
quadrant. Data represent mean ± SEM of nine rats per group. *P < 0.05, **P < 0.01, Tukey’s test versus only Aβ1-40-treated group; #P < 0.05,
##P < 0.01, ###P < 0.001, Tukey’s test versus sham group.
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neuronal loss was observed when they were treated with
3 μM Aβ1-40 for 24 hours (data not shown). This means
that 3 μM Aβ1-40 is sublethal for primary neurons while it
could induce significant elevation of TNF-α in microglia.
Besides, astrocytes seemed less sensitive to Aβ1-40 than
microglia, as up to 3 times higher concentration of Aβ1-40
and 48 hour stimulation increased astrocytic NO and TNF-
α productionsas compared to 3 μM Aβ1-40 and 24 hour
stimulation in microglia (Figure 1j-1k). In another words,
microglial overactivation might play the key role in neuro-
degeneration especially when the concentration of Aβ1-40
remains low and sublethal for neurons. The differences of
cognitive performances in MWM between rats of 12-day
recovery and 50-day recovery could also be explained in
this way: Aβ inoculation in hippocampus needs enough
time to form plaques and affect neurons in the brain, so Aβ
aggregates at low concentration would possibly activate
microglia at the very beginning, then parenchymal Aβ ag-
gregates would gradually affect neurons and result in more
severe cognitive impairments overtime.
LPS is able to elicit inflammatory responses in mono-
cytes and macrophages by activating multiple intracellu-
lar signaling pathways including NF-кB pathway and
three MAPK pathways (ERK, JNK, and p38). Activateddownstream transcription factors subsequently enter the
nuclei, bind to the promoter regions and initiate tran-
scriptions of various proinflammatory mediators such as
NO, TNF-α, IL-1β and so on [32,33]. In our study, 1 μg/
ml LPS indeed induced phosphorylation of MAPKs with
the peak level at 30 minutes. However, inhibition of
phosphorylation by SCM-198 in microglia could only be
observed for JNK, but not for ERK and p38. A recent
study in our lab found that SCM-198 protected against
TNF-α-induced inflammation in human umbilical vein
endothelial cells via inhibiting p38 activation, but not
ERK and JNK [34]. This divergence could be ascribed to
the different cell line and inflammatory initiator applied.
It is considered that LPS and TNF-α elicit cellular in-
flammatory responses mainly through Toll-like and TNF
receptors [35,36], respectively. Thus the two different
conclusions above could be valid but need further inves-
tigations. Inhibitory effects of SCM-198 on JNK phos-
phorylation and TNF-α release can be mimicked by
SP600125 (a JNK inhibitor), indicating that SCM-198 ex-
erts neuroprotective effects, at least partially, via inhibit-
ing both NF-кB and JNK pathways in microglia.
As Aβ deposits, neurofibrillary tangles and dystrophic
neurites are widely accepted hallmarks of AD. We herein
used pre-aggregated Aβ1-40 as the in vivo inflammation
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campal injections of Aβ1-40 or Aβ1-42 could activate glial
cells, elicit neuroinflammation and cause cognitive im-
pairments in rodents [37-39]. In our study, Aβ1-40 injec-
tions caused microglial activation, synaptophysin loss,
elevated phosphorylation of tau, ERK and NF-кB p65,
which were later significantly reversed by SCM-198. Our
unpublished data obtained from HPLC analysis showed
that SCM-198 administrated by gavage could be detected
in rat brains, which could be considered as supportive
evidence that SCM-198 could penetrate the blood-
brain barrier and directly exert neuroprotective effects
in CNS (Shi et al., unpublished data).
Interestingly, SCM-198 inhibited NF-кB and JNK
pathways in activated microglia, while it inhibited ERK
and NF-кB pathways in co-cultured neurons and rat
hippocampus. Possible explanations for the difference
were as follows: 1) in the co-culture paradigm, neurons
were directly stimulated by molecules released from pre-
treated microglia, but not directly by LPS and SCM-198,
which were removed from the media before microglia/
neuron co-culture; 2) Other studies have proved that ac-
tivated microglia upregulated p-ERK with no change in
total ERK in neurons and rodents’ brains and this eleva-
tion of p-ERK was accompanied by neuronal dysfunc-
tions and cognitive impairments of animals [40-42]; 3)
Hence, elevation of p-ERK in co-cultured neurons and
tissues was possibly an overall consequence of the inter-
actions between neurons and LPS- or Aβ-activated
microglia. Therefore, we concluded that SCM-198 could
either directly protect neurons from Aβ1-40 toxicity or
indirectly protect neurons against synaptophysin loss
and elevations of p-tau, p-ERK and p-p65 of NF-кB via
directly suppressing NF-кB and JNK pathways in acti-
vated microglia.
Further investigations will be necessary to clarify how
SCM-198 interacts with neurons and astrocytes. Several
other transgenic AD models will be needed to further
verify neuroprotective effects or unravel new potential
mechanisms of SCM-198. Taken together, our study, for
the first time, demonstrated that SCM-198 possessed
considerable anti-neuroinflammatory effect both in vitro
and in vivo and therefore protected co-cultured neurons
and improved overall cognitive performances of rats.
Hence, our data may provide new insights into AD treat-
ment with SCM-198 in the near future.
Conclusions
In summary, this is the first time that SCM-198 was
found to have considerable anti-inflammatory effects in
microglia and in Aβ1-40-injected SD rats, indicating its
potential as a drug candidate for AD treatment in the
future. SCM-198 may directly inhibit overactivated
microglia, maintain their ramified morphology, decreaseproinflammatory cytokines via NF-кB and JNK pathways
and therefore indirectly protect co-cultured neurons.
Besides, when directly applied to neurons, SCM-198
decreased neuronal death and LDH leakage caused by
Aβ1-40 stimulation. In vivo Aβ1-40 injection caused im-
pairments of spatial memory and microglial overactivation,
which were reversed by SCM-198 at 30 mg/kg and 60
mg/kg. In the chronic rat AD model, co-administration of
SCM-198 and DON resulted in better cognitive perfor-
mances of rats in the MWM test, indicating that SCM-198
could not only be used independently for AD treatment in
the future, but that it could be used as an adjuvant to im-
prove the therapeutic effect of DON. Further investigations
will be necessary to clarify how SCM-198 interacts
with neurons and astrocytes. Several other transgenic
AD models will be needed to further verify neuropro-
tective effects or unravel new potential mechanisms of
SCM-198.
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